NIH RFA · RMOD · UG3, UH3

RFA-RM-27-007: Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)

Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards

Opens Oct 23, 2026Next due date: Nov 23, 2026Expires Nov 24, 2026

The purpose of this Notice of Funding Opportunity (NOFO) is to solicit the development of innovative senescence technologies (SenTecs), or the adaptation of existing technologies focused on identification, characterization and understanding the biological consequences of senescent cell (SnC) heterogeneity in the context of the tissue environments and secretomes to facilitate novel strategies for modulating SnCs in vivo and for predicting the outcomes of targeting SnCs in human aging and in disease conditions. These are five-year, milestone-driven awards consisting of two phases. The first two years constitute the UG3 phase and are focused on SenTec development and demonstration of…

Full NOFO in the NIH Guide Apply on Grants.gov

NOFO number
RFA-RM-27-007
Type
RFA
Activity code
UG3UH3
Primary institute
RMOD
Clinical trials
Not Allowed
Posted
Oct 9, 2026
Opens
Oct 23, 2026
Expires
Nov 24, 2026

RFA-RM-27-007 due dates

1 application due date remains before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.

Application due dates and review cycles for RFA-RM-27-007
NewRenewal / Resubmission / Revision (as allowed)AIDS - New/Renewal/Resubmission/Revision, as allowedScientific Merit ReviewAdvisory Council ReviewEarliest Start Date
November 23, 2026Not ApplicableNot ApplicableMarch 2027May 2027July 2027

Funded projects

NIH RePORTER lists no awards under RFA-RM-27-007 in FY2022–FY2026, and it is a new NOFO rather than a reissue. Awards usually appear a few months after the first review cycle.

Participating institutes

4 NIH institutes and offices take applications under RFA-RM-27-007. Contact the program officer at the institute that fits your research before applying.

  • RMOD
  • NOFO
  • NCI · National Cancer Institute
  • none

Related notices

NIH lists no related notices for RFA-RM-27-007 yet.

Award terms

Application types allowed
New The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
Award budget
Applications must not exceed 400,000 in direct costs per year during the UG3 phase and 550,000 in direct costs per year during the UH3 phase.
Project period
The scope of the proposed project should determine the project period. The maximum project period is 5 years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
Funds available and number of awards
The NIH Common Fund Office of Strategic Coordination) intends to commit 5.4M Total Costs in FY2027 to fund up to 9 awards. Number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.

Related NOFOs

Other open NOFOs for UG3, UH3

Browse all open NIH NOFOs

About this page

GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.

Find who wins under this NOFO

NIH grant searchLook up awards by topic, PI, or institution.Find funded PIsInvestigators with recent NIH awards in your research area.Institute fit by topicWhich NIH institutes and institutions lead a research area.Funding trendsYear-by-year NIH award totals for any keyword.